TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

TrustFinance Global Insights
Feb 23, 2026
2 min read
80

Vision AI company ROC has successfully closed its initial public offering, raising $24 million in gross proceeds before expenses. The company's stock began trading on the Nasdaq Capital Market on February 20, 2026, under the ticker symbol ROC.
The Denver-based firm offered 4 million shares priced at $6.00 per share, which was at the high end of its expected range. ROC develops advanced biometric, video analytics, and mission intelligence solutions for defense, public safety, and digital commerce applications. The Benchmark Company served as the sole book-running manager for the offering.
ROC intends to use the net proceeds to hire personnel for growth initiatives and expand its neural-processing infrastructure for Vision AI algorithm development. The successful listing suggests strong investor confidence in the artificial intelligence and security technology sectors. The capital infusion is expected to accelerate ROC’s market expansion and technological capabilities.
ROC's public debut provides the necessary capital to scale its operations and enhance its competitive position. Market participants will be closely watching how the company leverages these funds to drive innovation and capture a larger market share in the rapidly evolving Vision AI landscape.
Q: How much did ROC raise in its IPO?
A: ROC raised gross proceeds of $24 million by offering 4 million shares at a price of $6.00 per share.
Q: What is ROC's primary business?
A: ROC is a Vision AI company that develops biometric and video analytics solutions for defense, public safety, and commerce.
Source: Investing.com

TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Related Articles

27 Mar 2026
Kailera Therapeutics Files for Nasdaq IPO